Please login to the form below

Not currently logged in

Genentech extends deal with Galapagos

Genentech has extended its drug discovery deal with Galapagos for a third time

Genentech, a member of the Roche Group, has extended its integrated contract drug discovery agreement with Galapagos' service division Argenta.

The agreement, which could be worth up to £21.5m (€23.4m), covers a number of drug discovery programmes that utilise Argenta's expertise in computer-aided drug design, medicinal chemistry, in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech.

The extended agreement also allows Genentech to continue placing projects directly into Galapagos' other service division, BioFocus, which will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services. 

Dr Chris Newton, senior vice-president of services of Galapagos, said: “The possibility for Genentech to continue placing projects directly with BioFocus also speaks to the complementary expertise and technological capabilities that Argenta and BioFocus possess.”

It is the third extension since the agreement was announced in December 2005.

18th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....